已收盤 09-19 16:00:00 美东时间
+0.020
+1.61%
ATAI Life Sciences NV : Jefferies Cuts Target Price to $5 From $6
08-14 13:25
The journal Psychopharmacology on Aug. 10 retracted three articles related to the use of MDMA for PTSD, the day after the U.S. FDA rejected the use of the psychedlic drug for the condition. Scientists...
08-12 23:50
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
07-31 20:00
成分股Vir Biotech收涨19.66%,诺瓦瓦克斯医药(NVAX)涨18.07%,Terns Pharmaceuticals、Protagonist T...
06-06 05:05
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD). Here's a look at what's moving psychedlic stocks:
06-05 22:58
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-18 01:14
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
05-16 08:12
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 19.05 percent increase over losses of $(0.21) per share from
05-15 19:57
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share...
05-15 19:57